



Trade Science Inc.

# Organic CHEMISTRY

An Indian Journal

Short Communication

OCAIJ, 8(9), 2012 [323-325]

## Synthesis and biological screening of 4-arylidene-1-(indan-1'-yl)-2-phenyl-5-oxo-imidazolines

V.P.Gohel, V.N.Patolia\*

Kamani Science College, Chemistry Department, Amreli, Gujarat, (INDIA)

Received: 13<sup>th</sup> December, 2011 ; Accepted: 30<sup>th</sup> December, 2011

### ABSTRACT

4-arylidene-1-(indan-1'-yl)-2-phenyl-5-oxo-imidazolines (2a-2l) have been synthesized. The products have been assayed for their biological screening against Gram +ve bacteria, Gram -ve bacteria and fungi. The products have been characterised by IR, <sup>1</sup>H NMR, Mass spectral studies, elemental analysis and TLC method. © 2012 Trade Science Inc. - INDIA

### KEYWORD

Imidazolines

### INTRODUCTION

Imidazolines are better therapeutic agents like antihistaminic<sup>[1]</sup>, antineoplastic<sup>[2]</sup>, antipyretic and analgesic<sup>[3]</sup>, anti-inflammatory<sup>[4]</sup> etc. With an aim to get better therapeutic agents, 4-arylidene-1-(indan-1'-yl)-2-phenyl-5-oxo-imidazolines (2a-2l) have been synthesised by the condensation of 1-aminoindan with different oxazolones. The oxazolones have been synthesised by Erlenmeyer reaction<sup>[5]</sup>

The products (2a-2l) were assigned by IR, <sup>1</sup>H NMR, Mass spectral data, TLC and elemental analysis. The physical data and biological screening with MIC are represented in TABLE 1 and comparable activity of synthesised products compare with known standard drugs are presented in TABLE 2 & TABLE 3.

### BIOLOGICAL SCREENING

The biological screening was determined by broth dilution method<sup>[6,7]</sup> using DMSO as a solvent. The activity was taken by Gram positive bacteria *S.aureus*, *S.pyogenes*, Gram negative bacteria *E.coli.*,

*P.aeruginosa* and antifungal activity against *Candida albicans*. The minimum inhibition concentration (MIC) was measured in µg/ml which is represented in TABLE 1. The products were compared with known standard drugs viz. Ampicillin, Chloramphenicol, Ciprofloxacin and Griseofulvin which is represented in TABLE 2 & TABLE 3.

### EXPERIMENTAL


All the melting point were measured by open glass capillary method and are uncorrected. IR absorption spectra (in cm<sup>-1</sup>) were recorded on a Shimadzu IR spectrophotometer using KBr pellet method, <sup>1</sup>H NMR spectra on Bruker (500MHz) spectrometer using DMSO-d<sub>6</sub> solvent, TMS as internal standard (chemical shift in δppm) and mass spectra on Joel 300eV. The purity of the compounds was routinely checked by TLC using silica gel-G.

### Synthesis of 4-(4"-methoxy benzylidene)-1-(indan-1'-yl)-2-phenyl-5-oxo-imidazoline (2d)

A mixture of 1-aminoindan (1.33g, 0.01M) and 4-

## Short Communication

### REACTION SCHEME



(4''-methoxy benzylidene)-2-phenyl-5-oxazolone (2.78g, 0.01M) in pyridine (10ml) was refluxed for 4 hrs at 120° in oil bath. The reaction mixture was poured into crushed ice, filtered, dried and crystallised from ethanol. Yield: 65.74%, mp: 164°C (Found: C: 79.00; H: 5.54; N: 7.06; C<sub>26</sub>H<sub>22</sub>O<sub>2</sub>N<sub>2</sub> Cald. C: 79.18; H: 5.58; N: 7.10%) IR (KBr)(cm<sup>-1</sup>): 2970(C-H str.asym), 2850(C-H str.sym), 1473(C-H def.asym), 3063(C-H str.aromatic), 1510, 1533(C=C str), 1373(C-N str), 1641(>C=O str), 1251(C-O-C str.), <sup>1</sup>H NMR (δppm): 3.7(S, 3H, -OCH<sub>3</sub>), 1.9-2.9(m, 5H), 7.1-7.9(m, 15H and =CH) m/z: 57, 77, 91, 105, 117, 132, 147, 174, 193, 237, 279, 394.

Similarly other compounds (2a-2l) were synthesised and their physical data are represented in TABLE 1.

TABLE 1 : The physical data and biological screening of compounds (2a-2l)

Compd.	R	mp°C	Antimicrobial Activity (MIC in µg/ml)				Antifungal Activity (MIC in µg/ml)	% of Nitrogen	
			Gram+ve bacteria		Gram-ve bacteria				
			S.aureus	S.pyogenes	E.coli	P.aeruginosa	C.albicans	Cald.	Found
2a	C <sub>6</sub> H <sub>5</sub> -	134	200	200	200	250	500	7.69	7.64
2b	2-OH-C <sub>6</sub> H <sub>4</sub> -	82	250	200	250	250	500	7.36	7.33
2c	4-OH-C <sub>6</sub> H <sub>4</sub> -	77	125	125	500	250	1000	7.36	7.34
2d	4-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub> -	164	200	200	200	250	1000	7.10	7.06
2e	2-Cl-C <sub>6</sub> H <sub>4</sub> -	71	250	250	500	500	>1000	7.02	7.00
2f	4-Cl-C <sub>6</sub> H <sub>4</sub> -	190	200	250	200	250	500	7.02	6.09
2g	2-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -	128	125	125	125	100	500	10.26	10.23
2h	3-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -	78	200	250	200	250	250	10.26	10.24
2i	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -	81	500	500	100	100	1000	10.26	10.23
2j	3-OCH <sub>3</sub> , 4-OH-C <sub>6</sub> H <sub>3</sub>	88	250	250	200	200	1000	6.82	6.78
2k	4-N-(CH <sub>3</sub> ) <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -	97	100	100	500	500	500	10.31	10.27
2l	C <sub>4</sub> H <sub>3</sub> O-(furfural)	78	250	250	250	200	1000	7.90	7.86

TABLE 2 : Compound showing comparable activity with known standard drugs:

Compound	S.aureus	S.pyogenes	E.coli	P.aeruginosa	C.albicans
(2a-2l)	2c, 2d, 2f, 2g, 2h, 2k	2c, 2g, 2k	2g, 2i	2g, 2i	2a, 2b, 2f, 2g, 2h, 2k

TABLE 3 : Activity of standard drugs (MIC in µg/ml)

Sr.No.	Drugs	S.aureus	S.pyogenes	E.coli	P.aeruginosa	C.albicans
1	Ampicillin	250	100	100	100	-
2	Chloramphenicol	50	50	50	50	-
3	Ciprofloxacin	50	50	25	25	-
4	Griseofulvin	-	-	-	-	500

**CONCLUSION**

4-arylidene-1-(indan-1'-yl)-2-phenyl-5-oxoimidazolines (2a-2l) have been synthesised. Compounds 2c, 2g, 2h, 2i, 2k shows good remarkable biological activity compared with known standard drugs.

**AKNOWLEDGEMENT**

The authors are thankful to principal, Kamani science college, Amreli for providing research facilities.

**REFERENCES**

- [1] R.R.Granshaw, G.M.Luke; Can.C.A., **1**, 190,306; Chem.Abstr., **98**, 1694 (1983).
- [2] Sumitemo Chemican Co.Ltd.; Jpn.Kokai Tbfefcyo Koho JP, **57**, 120, 576; Chem.Abstr., **98**, 16683j (1983).
- [3] C.R.Sarna, D.R.Sharidhar; Indian Pat.IM., **154**, 314 (1984); Chem.Abst., **105**, 133, 738 (1986).
- [4] S.Swamp, V.K.Saxena, S.R.Chaudhary; Indian J.Pharma.Sci., **51(4)**, 124-27 (1989).
- [5] A.F.M.Fahmy, M.O.A.Okabi; Indian J.Chem., **10**, 961-964 (1972).
- [6] Clinical Microbiology Procedure Handbook, Chapter-5, Henry d.Isenberg, 2<sup>nd</sup> Edition, **2**, 501.
- [7] Indian Journal of Chemistry, Section-b, **46b**, 550-553, March (2007).